Literature DB >> 9706825

The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock.

E R Bates1, R J Stomel, J S Hochman, E M Ohman.   

Abstract

Modern coronary care unit interventions have not reduced the high mortality rate associated with cardiogenic shock due to acute myocardial infarction. Results with thrombolytic therapy have also been disappointing because of poor infarct artery patency rates in a low coronary flow state. Percutaneous transluminal coronary angioplasty appears to be a beneficial intervention, but the technique is not available at most hospitals. Intraaortic balloon counterpulsation provides temporary hemodynamic and clinical improvement in the majority of patients with cardiogenic shock. The use of intraaortic counterpulsation to augment patency rates with thrombolytic therapy or to stabilize patients for transfer to a hospital with angioplasty services appears to be a promising strategy for hospitals without an interventional cardiac catheterization laboratory.

Entities:  

Mesh:

Year:  1998        PMID: 9706825     DOI: 10.1016/s0167-5273(98)00049-7

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Cardiogenic Shock.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

2.  Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry.

Authors:  Cristiano Guedes Bezerra; Eduardo Leal Adam; Mariana Lins Baptista; Giuliano Serafino Ciambelli; Liliane Kopel; Claudia Bernoche; Leonardo Nicolau Geisler Daud Lopes; Milena Frota Macatrão-Costa; Breno de Alencar Araripe Falcão; Silvia Gelas Lage
Journal:  Arq Bras Cardiol       Date:  2015-12-22       Impact factor: 2.000

3.  Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.

Authors:  G Montalescot; H R Andersen; D Antoniucci; A Betriu; M J de Boer; L Grip; F J Neumann; M T Rothman
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.